

Drug name	Therapeutic area	Primary route(s) of metabolism	Other more minor metabolic routes	Nature of biotransformation of main human circulating metabolite(s)	% circulating major metabolites in human mass balance study (if data found/relevant)
Bexagliflozin	Endocrinology (diabetes)	UGT1A9	CYP3A4	O-glucuronidation	
Capiversitib	Oncology (breast cancer)	CYP3A4 UGT2B7			
Elacestrant	Oncology (breast cancer)	CYP3A4 UGT	CYP2A6 CYP2C9	N-dealkylation and glucuronidation	Glucuronide at 41%
Iptacopan	Rare diseases (paroxysmal nocturnal hemoglobinuria)	CYP2C8 UGT1A1	CYP2D6 UGT1A3/1A8	M2: Oxidation M8 & M9: Acyl glucuronidation	M8: 8.1% M9: 5.2%
Pirtobrutinib	Oncology (mantle cell lymphoma)	UGT1A8/UGT1A9 CYP3A4		M1: pyrazole ring opening M2: N-glucuronidation M3: O-glucuronidation/oxidation	
Repotrectinib	Oncology (non-small cell lung cancer)	CYP3A4 Secondary glucuronidation			
Ritlectinib	Dermatology (Alopecia areata)	Multiple GSTs & CYPs		M1: GSH conjugation M2: Cysteine conjugation M3: NAC conjugation M4 & M5: oxidation	M2: 16.5%
Sotagliflozin	Cardiology (reduce the risk of death due to heart failure)	UGT1A9	CYP3A4 UGT1A1/2B7	M19: O-glucuronidation	94.3%
Vamorolone	Rare diseases (Duchenne muscular dystrophy)	Multiple CYPs & UGTs		Reduction Hydroxylation Glucuronidation	